NAGLU

Across TCGA pan-cancer cohorts, NAGLU mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NAGLU data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NAGLU mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NAGLU expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where NAGLU mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	1.000	0.838	.001	16	view →
HNSC	OS	Quartile	All	0.925	1.000	.019	11	view →
LUAD	DFS	Median	All	0.654	0.834	.007	10	view →
UCEC	DFS	Median	All	0.936	1.000	.021	8	view →
GBM	DFS	Median	All	0.205	0.319	.025	6	view →
PDAC	DFS	Tertile	II,III,IV	0.193	0.404	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NAGLU–CCRCC (OS)

Open the CCRCC breakdown →